Skip to content

Exploring the effects of depression intervention on memory function and its neural mechanisms in patients with mild cognitive impairment

Exploring the effects of depression intervention on memory function and its neural mechanisms in patients with mild cognitive impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086712
Enrollment
Unknown
Registered
2024-07-09
Start date
2024-08-01
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment

Interventions

control group:Conventional cognitive intervention

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The 2006 MCI International Working Group and the 2008 Clinical Research Guidelines for Mild Cognitive Impairment in China (? Cognitive complaints from patients and/or family members; ? Patients and/or informants reporting a relative decline in cognitive function over the past year; ? Cognitive impairment confirmed by clinical evaluation, manifested as impairment in memory and/or other cognitive domains; ? Preservation of daily life activities, complex instrumental functions not impaired or only very mild impairment; ? No dementia); 2. Age range from 50 to 85 years old; 3. 8 = HAMD-17 = 24 points; 4. Clinical Dementia Rating Scale (CDR) 0.5 points; 5. No contraindications for functional magnetic resonance imaging and able to cooperate in completing the examination; 6. Capable of cooperating in completing all training programs and including neuropsychological tests; 7. Agree to participate in this clinical trial and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. There are paramagnetic metal implants such as heart stents, pacemakers, dentures, and cochlear implants in the body; 2. Existence of intractable epilepsy, normal stress induced hydrocephalus, brain tumors and other neurological diseases; 3. Individuals diagnosed with mental retardation, bipolar disorder, schizophrenia, etc. by DSM-5 or ICD-10, or currently taking antipsychotic drugs; 4. Severe heart and lung diseases and liver and kidney dysfunction; 5. Severe visual and auditory dysfunction; 6. The researchers believe that participants who are not suitable to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
auditory verbal learning test,AVLT;

Secondary

MeasureTime frame
WMS-RC;ERP;Resting state fMRI;Montreal Cognitive Assessment;Hamilton Depression Rating Scale,HAMD-17;Resting state alpha, beta, ?, and gamma waves of EEG;Functional near-infrared brain resting state data;

Countries

China

Contacts

Public ContactLu Xiao

The First Affiliated Hospital of Nanjing Medical University

1010464860@qq.com+86 134 0413 9812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026